Lung – Clinical Value of Diagnostics
https://clinicalvalue.com
Fri, 02 May 2025 08:10:33 +0000en-US
hourly
1 https://wordpress.org/?v=6.6.2https://i0.wp.com/clinicalvalue.com/wp-content/uploads/2023/01/apple-touch-icon.png?fit=32%2C32&ssl=1Lung – Clinical Value of Diagnostics
https://clinicalvalue.com
3232225041835Global Talks Lung Cancer Forum
https://clinicalvalue.com/event/global-talks-nsclc-treatment-webinar/
Mon, 22 Jul 2024 01:55:32 +0000https://clinicalvalue.com/?post_type=event&p=8841Watch this webinar to get updates on advancements in lung cancer treatment, including resectable NSCLC, thoracic surgery, neoadjuvant immunotherapy....
In this webinar, experts in lung cancer from around the globe discuss the latest advancements in lung cancer treatment. Watch the webinar recording to get updates on treatment options for resectable NSCLC, thoracic surgery, and neoadjuvant immunotherapy for NSCLC.
You are viewing an International Congress run by Roche and provided to international HCPs from around the world. Please note that prescribing information provided here may vary depending on local approval in each country. For purposes of Global Talk, best efforts were undertaken by Roche to ensure compliance with the applicable law and regulations, however, you should review your local prescribing information and consult directly the local affiliate of the relevant Company to address any questions.
Join us for an insightful webinar discussion on the use of precision
oncology and lung cancer management in the Asia-Pacific (APAC) region. This webinar
features leading oncologists who will share their clinical
expertise and discuss the application of precision oncology
and updated lung cancer treatment in APAC region, across 2
consecutive sessions:
Session 1
Timely Diagnosis to Enable Personalized Healthcare with
Clinical Decision Support Tools
Time
14:30 - 16:00
Topics
The value of precision oncology, gaps in implementation
process, and updates on Taiwan molecular tumour board (MTB)
consensus
Overcoming barriers to precision oncology implementation
with digital solutions
Updates on comprehensive genomic profiling (CGP) validation
and evidence
Understand the comprehensive treatment journey, from initial
strategy to post-EGFR progression, for advanced non-squamous NSCLC
Speakers
Prof. Tony Mok
Chairman, Department of Clinical Oncology, The Chinese University of Hong Kong
Prof. Virote Sriuranpong
Department of Internal Medicine, Faculty of Medicine,
Chulalongkorn University, Thailand
Dr. Aaron Tan
Senior Resident Physician, National Cancer Centre Singapore
Prof. Byoung Chul Cho
Chief, Lung Cancer Center, Yonsei Cancer Center, Korea
Agenda
Time
Topic
Speakers
16:15 - 16:30
Opening remarks
Prof. Tony Mok
16:30 - 17:00
Clinical Considerations for Metastatic ALK+ Patients in the
Era of Multiple Treatment Options
Prof. Virote Sriuranpong
17:00 - 17:15
Panel Discussion
All
17:15 - 17:45
Navigating First-line Therapies in Advanced Non-Squamous NSCLC: From Initial Strategies to Post-EGFR Progression Challenges
Dr. Aaron Tan
17:45 - 18:00
Panel Discussion
All
18:00 - 18:30
The Evolving Landscape in Early Lung Cancer Management with Systemic Treatment for Driver Mutation and PD-L1+ Patients
Prof. Byoung Chul Cho
18:30 - 18:45
Panel Discussion
All
18:45 - 18:50
Closing
Prof. Tony Mok
Date:
30thNovember 2023
Time:
14:30 - 18:50
(GMT+08:00)
11:30 - 15:50
(Karachi)
12:00 - 16:20
(Delhi)
13:30 - 17:50
(Bangkok / Ho Chi Minh / Jakarta)
14:30 - 18:50
(Hong Kong / Kuala Lumpur /
Singapore)
15:30 - 19:50
(Seoul / Tokyo)
16:30 - 20:50
(Melbourne)
18:30 - 22:50
(New Zealand)
This material represents personal viewpoint and is intended to
promote the communication and exchange of medical information, and
shall be used by healthcare professionals as a reference only.
This material may contain medicinal products or clinical
indications that have not yet been approved in your country.
Please refer to the locally approved package insert for detailed
prescription information.
]]>6859Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
https://clinicalvalue.com/asian-esmo-nsclc-guidelines-advanced-lung-cancer/
Fri, 19 May 2023 09:49:29 +0000https://clinicalvalue.com/?p=6954This guideline aims to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). ...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of early and locally-advanced non-small-cell lung cancer (NSCLC) was published in 2017, and covered the diagnosis, staging, management and treatment of both early stage I and II disease and locally-advanced stage III disease. At the ESMO Asia Meeting in November 2018, it was decided by both the ESMO and the Korean Society of Medical Oncology (KSMO) to convene a special face-to-face guidelines meeting in 2019 in Seoul.
The aim was to adapt the ESMO 2017 guidelines to take into account potential differences related to ethnicity, cancer biology and standard practices associated with the treatment of locally-advanced, unresectable NSCLC in Asian patients. These guidelines represent the consensus opinions reached by those experts in the treatment of patients with lung cancer who represented the oncology societies of Korea (KSMO), China (CSCO), India (ISMPO), Japan (JSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and it was independent of both local current treatment practices and the treatment availability and reimbursement situations in the individual participating Asian countries.
]]>6954National Comprehensive Cancer Network (NCCN) guidelines for lung cancer
https://clinicalvalue.com/national-comprehensive-cancer-network-nccn-guidelines-for-lung-cancer/
Fri, 19 May 2023 09:22:12 +0000https://clinicalvalue.com/?p=6853The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care. Access the NSCLC and SCLC guidelines. ...
National Comprehensive Cancer Network NSCLC and SCLC guideline recommendations for cancer care decision-making
Quick Summary
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions to assist in the decision-making process of individuals involved in cancer care (including physicians, nurses, pharmacists, payers, patients and their families), with the ultimate goal of improving patient care and outcomes.
The NCCN Guidelines provide recommendations based on the best evidence available at the time they are derived, and are continuously updated and revised to reflect new data and clinical information that may add to or alter current clinical practice standards.
Read the latest NCCN lung cancer guidelines below:
